Skip to content
New platform coming soon — AI-Based Analysis with Human-Generated Insights
Stock Target Advisor Stock Target Advisor Market intelligence
  • Research
  • Market Analysis
  • Analyst Ratings
  • Top Stocks
  • Contact

Browse research

Author: Muzzammil Ahmad

Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
Microsoft Inches Closer to Overtaking Apple in Valuation Race
Market News & Insights Jan 5, 2024

Microsoft Inches Closer to Overtaking Apple in Valuation Race

Microsoft Corporation (MSFT: NSD) is steadily closing the gap with Apple Inc. (AAPL: NSD) in terms of market capitalization. Microsoft’s market capitalization…

#Dividends #Mergers & Acquisitions #technology stocks
Stock Market 2024 Navigating Turbulence or Smooth Sailing
Market News & Insights Jan 1, 2024

Stock Market 2024: Navigating Turbulence or Smooth Sailing?

The year 2024 is here and investors are keen to learn about the stock market’s performance in the previous year. With global…

#Artificial Intelligence #Cryptocurrency #Earnings
add stock symbols: "3M Co: Jefferies lowered its price target to $160 from $180, citing a weaker macro backdrop and increased demand volatility from tariffs. Bank of America Corp: The bank agreed to pay $72.5 million to settle a lawsuit tied to Jeffrey Epstein-related allegations, resolving the matter without admitting wrongdoing. BlackRock Inc: The firm participated in a $57.64 million funding round for IQM Quantum Computers to support its growth and upcoming public listing. Boston Scientific Corp: Jefferies cut its price target to $110 from $120 due to lower valuation multiples and limited upside from recent developments. Chevron Corp: Its Wheatstone LNG facility in Australia will take several weeks to return to full production after cyclone damage, contributing to global supply disruptions. Eli Lilly and Co: The company is seeking higher UK drug prices and rebate reforms to support investment, while also entering a potential $2.75 billion AI drug development partnership. Hartford Insurance Group Inc: KBW downgraded the stock to Market Perform from Outperform due to concerns over liability reserve adequacy. Nexstar Media Group Inc: A U.S. judge ordered the company to keep Tegna’s assets separate temporarily while reviewing antitrust concerns related to its $3.54 billion acquisition. Nike Inc: The company is facing mounting challenges in China from weaker consumer demand and rising competition from domestic brands, pressuring its market share. Nvidia Corp.  is now trading at its lowest price-to-earnings multiple in seven years as broader market selloffs driven by Middle East war concerns and growing skepticism around AI valuations weigh on the stock, despite its central role in the AI boom. Sysco Corp: Sysco announced a $29 billion acquisition of Jetro Restaurant Depot to expand its reach in the independent restaurant market, though shares fell on concerns about increased debt financing."
Market News & Insights Dec 28, 2023

Nvidia: Wall Street’s Top Stock to Watch in 2024

Nvidia (NVDA: NSD) is considered by Wall Street analysts as the top stock pick for 2024. The company is a leading provider…

#Artificial Intelligence #Mergers & Acquisitions #technology stocks
Apple's Smartwatch Business Gets A Boost After Court Decision
Market News & Insights Dec 28, 2023

Apple’s Smartwatch Business Gets A Boost After Court Decision

Apple (AAPL: NSD) has received permission to continue selling its latest smartwatches after a temporary pause on the import ban imposed by…

#Earnings
Cytokinetics Stock Surges on Promising Phase 2 Trial Results
Market News & Insights Dec 28, 2023

Cytokinetics Stock Surges on Promising Phase 2 Trial Results

Cytokinetics Inc’s stock (CYTK: NSD) surged by over 30% after positive Phase 2 trial results of its lead drug candidate, omecamtiv mecarbil,…

#analyst ratings #Earnings

Posts pagination

Previous 1 … 273 274 275 276 277 … 301 Next
Stock Target Advisor

Timely market news, analyst rating changes, and practical investment research for investors around the world.

  • Research
  • Analyst Ratings
  • Market Analysis
  • Top Stocks
  • About Us
  • Contact Us
  • Contribute a Post
© 2026 Stock Target Advisor. All rights reserved.